Dabrafenib/Dabrafenib’s 2024 medical insurance price
Dabrafenib is a targeted therapy drug mainly used to treat BRAF V600 mutation-positive melanoma. This drug blocks the growth and spread of tumor cells by inhibiting the activity of the BRAF protein. BRAF gene mutations are relatively common in melanoma patients, and the use of dabrafenib can significantly improve the treatment effect and survival rate of these patients. In addition, dabrafenib is also used to treat certain other types of tumors, such as BRAF V600 mutation-positive non-small cell lung cancer.
In China, dabrafenib received drug registration approval in 2019 and was officially launched on the market. As the country attaches great importance to anti-cancer drug policies, the launch of dabrafenib provides a new treatment option for patients. The launch of the drug marks China's continued progress in the field of targeted drug therapy. The specification 75mg*120 capsules available in China may cost more than RMB 10,000 per box.
Regarding medical insurance prices, the specific price of dabrafenib varies in different regions, hospitals and pharmacies, but there is usually a unified reference price. In China, dabrafenib has been included in the medical insurance catalog in some regions, which has significantly reduced the cost paid by patients. However, due to different medical insurance policies and reimbursement ratios in different places, the specific medical insurance prices may vary. Patients should consult local medical institutions or medical insurance departments before use to learn about detailed reimbursement policies and out-of-pocket expenses to ensure they receive the appropriate financial support.
Although dabrafenib's efficacy has shown well in clinical studies, not all patients will respond well to it. Therefore, when using this drug, patients should undergo genetic testing to confirm the presence of theBRAF V600 mutation to ensure the effectiveness of the treatment. At the same time, because targeted therapy may be associated with some side effects, patients should maintain close communication with their doctors during treatment and adjust the treatment plan in a timely manner to obtain the best treatment effect and quality of life.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)